Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: Are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?

Molecular Diagnosis and Therapy

Volumn 15, Issue 5, 2011, Pages 277-283

  Faria Sarasqueta, Arantza ^a,b   Van Lijnschoten, Gesina ^a   Lemmens, Valery E P P ^c   Rutten, Harm J T ^d   Van Den Brule, Adriaan J C ^a  

^a Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

^b FONTYS UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^c The Netherlands   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

Author keywords

Biomarkers; Colon cancer; Oxaliplatin; Pharmacogenetics; Platinum complexes

Indexed keywords

CAPECITABINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA REPAIR; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 80455129755     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11592080-000000000-00000     Document Type: Article

References (26)

1. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005 Apr; 31 (2): 90-105 (Pubitemid 40542888)
2. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl JMed 2004 Jun 3; 350 (23): 2343-51 (Pubitemid 38702845)
3. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007 Jun 1; 25 (16): 2198-204 (Pubitemid 46954643)
4. Cronin DP, Harlan LC, Potosky AL, et al. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 2006 Oct; 101 (10): 2308-18 (Pubitemid 44477559)
5. van Steenbergen LN, Rutten HJ, Creemers GJ, et al. Large age and hospitaldependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol 2010 Jun; 21 (6): 1273-8
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007 Feb; 33 (1): 9-23 (Pubitemid 46137553)
7. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008 Mar 1; 14 (5): 1291-5 (Pubitemid 351413906)
8. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-54 (Pubitemid 39037082)
9. Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2/XPD polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011 Mar 15; 17 (6): 1632-40
10. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006 Sep 10; 24 (26): 4333-9 (Pubitemid 46630792)
11. Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009 Aug; 19 (8): 613-25
12. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001 Feb 15; 61 (4): 1354-7 (Pubitemid 34292555)
13. Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 1): 2101-8
14. Pare L, Marcuello E, Altes A, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/ 5-fluorouracil as first-line chemotherapy. Br JCancer 2008 Oct 7; 99 (7): 1050-5
15. Park DJ, Stoehlmacher J, ZhangW, et al. AXeroderma pigmentosum groupD gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001 Dec 15; 61 (24): 8654-8 (Pubitemid 34013872)
16. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003 Mar; 1 (3): 162-6
17. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007 April 1; 25 (10): 1247-54 (Pubitemid 46640571)
18. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005 Sep 1; 11 (17): 6212-7 (Pubitemid 41262950)
19. Huang MY, Fang WY, Lee SC, et al. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 2008; 8: 50
20. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000 Mar; 16 (3): 555-60
21. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000 Apr; 21 (4): 551-5 (Pubitemid 30214005)
22. Kweekel DM, Gelderblom H, Antonini NF, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur JCancer 2009 Mar; 45 (4): 572-8
23. Hendifar A, Yang D, Lenz F, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009 Oct 15; 15 (20): 6391-7
24. Paulson EC, Wirtalla C, Armstrong K, et al. Gender influences treatment and survival in colorectal cancer surgery.Dis ColonRectum2009Dec; 52 (12): 1982-91
25. Ratto C, Sofo L, Ippoliti M, et al. Prognostic factors in colorectal cancer: literature review for clinical application. Dis Colon Rectum 1998 Aug; 41 (8): 1033-49 (Pubitemid 28369295)
26. Gordon MA, Zhang W, Yang D, et al. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2010 Jan; 12 (1): 27-39